What is it about?

Several studies revealed the beneficial role of angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) in experimental animal models of arthritis. The newly approved ARBs, such as telmisartan and azilsartan, demonstrated potent anti-inflammatory activity in animal models through mechanisms not related to RAS blockade

Featured Image

Why is it important?

For the first time, we reported that azilsartan may improve the effects of methotrexate on the clinical scores and certain inflammatory biomarkers of patients with active RA.

Perspectives

Publishing these data was a great pleasure as it has co-authors with whom I have had long-standing collaborations. These data also highlighted the issue of the important outcomes of blocking RAS with the new generation of ARBs, like Azilsartan, to get a potent anti-inflammatory effect. This approach may have many clinical applications for the treatment of inflammatory disorders.

Professor Saad Abdulrahman Hussain
Al-Rafidain University College, Faculty of Pharmacy, Baghdad, Iraq

Read the Original

This page is a summary of: Azilsartan as “Add-On” Treatment with Methotrexate Improves the Disease Activity of Rheumatoid Arthritis, BioMed Research International, January 2018, Hindawi Publishing Corporation,
DOI: 10.1155/2018/7164291.
You can read the full text:

Read
Open access logo

Contributors

The following have contributed to this page